CAR T cell therapy—principle and clinical trial overview

Slides:



Advertisements
Similar presentations
Chimeric antigen receptors (CAR)
Advertisements

Manuscript summary Chronic Lymphoid Leukemia (CLL) Background Genetically engineering T cells Patient treatment history Engineered T cell therapy and.
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Volume 12, Issue 5, Pages (November 2005)
chimeric antigen receptor T-cell therapy for ALL
Professor John Gribben Barts Cancer Institute
Figure 1. Functional classification of positive-acting transcription factors. Major functional groups are shown in black; specific examples are illustrated.
Trinity College Dublin 12 April 2018 Hugh McMahon
Renier Brentjens, MD, PhD
Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Research Techniques Made Simple: CAR T-Cell Therapy
Figure 1 Chimeric antigen receptor (CAR) structures
Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.
Immunology Cell Volume 100, Issue 1, Pages (January 2000)
Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?
CAR T cell therapy—principle and clinical trial overview
Figure 1 CAR-T-cell design
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Volume 134, Issue 1, Pages (January 2008)
CAR T cell dose and percentages of CAR‐positive cells within CAR T cell products CAR T cell dose and percentages of CAR‐positive cells within CAR T cell.
Daniel Abate-Daga, Marco L Davila  Molecular Therapy - Oncolytics 
ADOPTIVE T CELL THERAPY
Figure 3 Structure of different types of T-cell-engaging antibodies
Volume 22, Issue 3, Pages (March 2014)
Miki Ando, Hiromitsu Nakauchi  Experimental Hematology 
Targeted Therapeutics
Clinical testing of calcineurin inhibitors cyclosporine A and tacrolimus in autoimmune disorders Clinical testing of calcineurin inhibitors cyclosporine.
Figure 2 Approaches to improve CAR-T-cell therapy
Expression and occupancy of a set of transcription factors corresponding to the identified motifs at FAIRE peaks Expression and occupancy of a set of transcription.
Titratable control of engineered therapeutic T cells through an ON-switch chimeric antigen receptor. Titratable control of engineered therapeutic T cells.
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
The Other Face of Chimeric Antigen Receptors
Volume 3, Issue 5, Pages (May 2003)
Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.
Volume 23, Issue 4, Pages (April 2015)
Research Techniques Made Simple: CAR T-Cell Therapy
Properties of proteins and residues with frequent hotspot mutations
Quantitative Imaging Approaches to Study the CAR Immunological Synapse
TIGIT and CD226: Tipping the Balance between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit  Kristen E. Pauken,
Association of AIM2, RIG‐I and NLRP3 inflammasomes with better survival in NPC patients.A.Overexpression of ASC, caspase‐1 and IL‐1β proteins as well as.
The Pharmacology of T Cell Therapies
Figure 1 Mechanisms of action of immunotherapy modalities
Volume 8, Issue 3, Pages R73-R75 (January 1998)
André Schiefner, Michaela Gebauer, Antonia Richter, Arne Skerra 
Volume 25, Issue 11, Pages (November 2017)
Normal priming and expansion of functional T cells in the spleen during concurrent co‐infection Normal priming and expansion of functional T cells in the.
New Cell Sources for T Cell Engineering and Adoptive Immunotherapy
Cancer Modeling in the Modern Era
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse  Saad S. Kenderian, David L. Porter,
Live and Let Die: A New Suicide Gene Therapy Moves to the Clinic
Chimeric antigen receptor T-cell therapy for solid tumors
by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A
by Rupert Handgretinger, Peter Lang, and Maya C. André
Genomewide profiling of chromatin accessibility in prostate cancer specimens Genomewide profiling of chromatin accessibility in prostate cancer specimens.
Cell-mediated immunity Regulation of the immune response
Manufacturing and delivery pipeline of genetically modified T-cell therapies. Manufacturing and delivery pipeline of genetically modified T-cell therapies.
Genetically modified TCRs for cancer immunotherapy.
Engineering of Chimeric Antigen Receptor therapy.
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
Sites and Stages of Autoreactive B Cell Activation and Regulation
Molecular Therapy - Nucleic Acids
A schematic presentation of secreted, endocytic, and signaling pattern-recognition receptors. A schematic presentation of secreted, endocytic, and signaling.
Fig. 1 Engineered T cells: design of TCR versus CAR T cells.
CAR T cell immunotherapy for human cancer
Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)
Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
Hildegard Büning, Arun Srivastava 
Presentation transcript:

CAR T cell therapy—principle and clinical trial overview CAR T cell therapy—principle and clinical trial overview (A) The CAR T cell therapy process. T cells are isolated from blood of the patient or a donor, activated, and then genetically engineered to express the CAR construct (an example shown in gray above the vector particle in violet). After ex vivo expansion of the CAR T cells, they are formulated into the final product. The patient undergoes either a conditional chemotherapy or the CAR T cell product is directly infused. (B) Schematic representation of a T cell receptor (TCR) and four types of chimeric antigen receptors (CARs) being displayed on the surface of a T cell while contacting their antigen (red) on the tumor cell. The single‐chain variable fragment (scFv) as ligand‐binding domain mediating tumor cell recognition in CARs is shown in light blue with the VH and VL domains being connected via a long flexible linker and transmembrane domain to intracellular signaling domains. Pro‐inflammatory cytokines or co‐stimulatory ligands expressed by the CAR T cells are depicted for the 4th generation. (C) Overview of so‐called smart CAR T cells products. Pooled CAR T cell products consist of two or more single‐targeting CAR T cell types with distinct antigen specificities. Multi‐CAR T cells harbor several CAR molecules with different antigen specificities. A tandem CAR T cell expresses a CAR construct harboring two ligand‐binding domains with different antigen specificities. In a conditional CAR T cell activation and co‐stimulation are separated on two CAR constructs recognizing different target antigens. In the split CAR construct the ligand‐binding or signaling domain is physically separated allowing controlled CAR T cell activation. iCAR T cells additionally express a receptor engineered to recognize an antigen expressed on normal tissue to provide an inhibitory signal in turn. In addition CAR T cells can be equipped with suicide genes or switches (e.g., iCasp9) allowing ablation of CAR T cells. (D) Left, status of published CAR T cell gene therapy trials or trials registered at ClinicalTrials.gov including long‐term follow‐up studies. The status of one trial is unknown and not listed. The total number of clinical trials (dark blue bars) is compared to published clinical trials (light blue bars). The asterisk indicates zero trials. Right, phases of CAR T cell gene therapy trials. Long‐term follow‐up studies are not included. For nine trials, the phase classification is unknown. The asterisk indicates zero trials. Jessica Hartmann et al. EMBO Mol Med. 2017;9:1183-1197 © as stated in the article, figure or figure legend